Silence Therapeutics' divesiran hits 88% response rate in rare blood cancer trial

In a 48-person Phase 2 trial, Silence Therapeutics' experimental drug divesiran achieved a clinical response in 88% of patients with polycythemia vera — a rare blood cancer marked by runaway red blood cell production. Only 19% of patients on placebo responded. The results position divesiran as a potential competitor to a drug from Takeda Pharmaceuticals that is nearing regulatory approval.